Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Acne Vulgaris is an inflammatory skin disorder that is common among adolescents and young adults. Acne is defined as a chronic inflammatory dermatosis which consists of open comedones (blackheads), closed comedones (whiteheads) and inflammatory lesions.1 There are many ways to combat acne, one of which is to stop the effects of androgens on androgen receptors. Here we will review Clascoterone, a medication approved for the treatment of acne. Clascoterone is the first topical medication to target the hormonal pathogenesis of acne. It was approved by the FDA in 2020 and is effective in treatment of acne vulgaris in patients 12 years of age and older.2
Keywords
Acne vulgaris, androgen receptor inhibitor, clascoterone, topical androgen receptor inhibitor, Androgen Receptor Antagonists, Cutaneous Administration, Topical Administration
Disciplines
Dermatology | Medicine and Health Sciences | Pathological Conditions, Signs and Symptoms | Pharmaceutical Preparations | Skin and Connective Tissue Diseases | Therapeutics
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.186_2024
Included in
Dermatology Commons, Pathological Conditions, Signs and Symptoms Commons, Pharmaceutical Preparations Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons
Updates to Acne Vulgaris Treatment: A Review of a Topical Androgen Receptor Inhibitor
Acne Vulgaris is an inflammatory skin disorder that is common among adolescents and young adults. Acne is defined as a chronic inflammatory dermatosis which consists of open comedones (blackheads), closed comedones (whiteheads) and inflammatory lesions.1 There are many ways to combat acne, one of which is to stop the effects of androgens on androgen receptors. Here we will review Clascoterone, a medication approved for the treatment of acne. Clascoterone is the first topical medication to target the hormonal pathogenesis of acne. It was approved by the FDA in 2020 and is effective in treatment of acne vulgaris in patients 12 years of age and older.2